Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TBZ6
UPID:
TM10A_HUMAN
Alternative names:
RNA (guanine-9-)-methyltransferase domain-containing protein 2; tRNA (guanine(9)-N(1))-methyltransferase TRMT10A
Alternative UPACC:
Q8TBZ6; B2R8X7; Q9Y2T9
Background:
tRNA methyltransferase 10 homolog A (TRMT10A) is a pivotal enzyme in cellular function, catalyzing the methylation of guanine at position 9 in tRNAs. This modification is crucial for the stability and function of tRNA molecules, impacting protein synthesis. TRMT10A is known by alternative names such as RNA (guanine-9-)-methyltransferase domain-containing protein 2.
Therapeutic significance:
TRMT10A's mutation is linked to Microcephaly, short stature, and impaired glucose metabolism 1, a disease marked by severe developmental issues and metabolic dysfunction. Understanding TRMT10A's role could lead to novel therapeutic strategies for managing this condition.